Pathophysiology Quiz: Hyperkalemia In Renal Failure
20 questions · exam conditions
0:00
Hyperkalemia In Renal FailureQuestion 1 of 20

A patient with severe rhabdomyolysis develops oliguric acute kidney injury. The serum potassium is 7.8 mEq/L. The severity of this hyperkalemia is best explained by the combination of a massive endogenous potassium load and:

suppression of aldosterone secretion by the high potassium load.
rhabdomyolysis-induced metabolic alkalosis, which shifts potassium into the ECF.
an adaptive upregulation of potassium reabsorption in the proximal tubule.
a profound failure of distal tubular secretion due to diminished luminal flow.
← Back to quizzes

Pathophysiology Quiz

Pathophysiology Quiz: Hyperkalemia In Renal Failure

Practice Hyperkalemia In Renal Failure in Pathophysiology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Hyperkalemia In Renal Failure, giving you a quick way to practice the rules, question types, and explanations that matter most for Pathophysiology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient with severe rhabdomyolysis develops oliguric acute kidney injury. The serum potassium is 7.8 mEq/L. The severity of this hyperkalemia is best explained by the combination of a massive endogenous potassium load and:

  1. suppression of aldosterone secretion by the high potassium load.
  2. rhabdomyolysis-induced metabolic alkalosis, which shifts potassium into the ECF.
  3. an adaptive upregulation of potassium reabsorption in the proximal tubule.
  4. a profound failure of distal tubular secretion due to diminished luminal flow. (correct answer)
Explanation: When you encounter severe hyperkalemia in the setting of acute kidney injury, think about both the source of potassium and the kidney's impaired ability to eliminate it. This question tests your understanding of how renal potassium handling fails in AKI. The correct answer is D because oliguria profoundly impairs distal tubular potassium secretion. Normally, about 90% of filtered potassium is reabsorbed in the proximal tubule and loop of Henle, while the distal nephron (especially principal cells in the collecting duct) actively secretes potassium into urine. This secretion depends critically on adequate tubular flow rate. In oliguric AKI, the dramatically reduced urine flow means less sodium delivery to the distal nephron, which directly impairs the Na-K-ATPase pump activity that drives potassium secretion. Combined with the massive potassium release from destroyed muscle cells in rhabdomyolysis, this creates severe hyperkalemia. Option A is incorrect because high potassium actually stimulates aldosterone secretion, not suppresses it. Option B contains a fundamental error—rhabdomyolysis causes metabolic acidosis (not alkalosis) from organic acid release, and acidosis shifts potassium out of cells, worsening hyperkalemia. Option C is wrong because the proximal tubule normally reabsorbs most filtered potassium regardless, and this doesn't explain the secretory failure. Remember this key principle: in AKI with oliguria, think about flow-dependent processes. Potassium secretion requires adequate distal flow, so severe oliguria creates a "perfect storm" when combined with increased potassium loads from tissue breakdown.

Question 2

A patient with CKD Stage 4 (GFR 28 mL/min) and hypertension has a stable serum K+ of 5.2 mEq/L. They are started on hydrochlorothiazide. Assuming GFR and dietary intake remain constant, this medication would be expected to alter serum potassium by which mechanism?

  1. Decreasing it, by increasing sodium delivery to the collecting duct, which enhances the secretory gradient. (correct answer)
  2. Increasing it, by causing volume contraction and reducing the filtered load of potassium.
  3. Increasing it, by directly inhibiting the ROMK channels in the principal cells.
  4. Causing no significant change, as thiazide diuretics are ineffective at this level of GFR.
Explanation: When you encounter questions about diuretics and electrolyte balance, focus on how each drug class affects sodium delivery to different nephron segments and the downstream effects on potassium handling. Hydrochlorothiazide blocks the NCC transporter in the distal convoluted tubule, preventing about 5-10% of filtered sodium from being reabsorbed. This unabsorbed sodium continues downstream to the collecting duct, where it's handled by epithelial sodium channels (ENaC). When more sodium is delivered here, principal cells increase sodium reabsorption, which creates a more negative luminal charge that enhances the electrochemical gradient for potassium secretion through ROMK channels. Additionally, increased sodium reabsorption stimulates the renin-angiotensin-aldosterone system, further promoting potassium loss. This mechanism works even with reduced GFR because the collecting duct remains responsive to changes in sodium delivery. Option B incorrectly suggests volume contraction reduces filtered potassium load enough to cause hyperkalemia, but the enhanced secretory gradient from increased distal sodium delivery overwhelms this minor effect. Option C is wrong because thiazides don't directly inhibit ROMK channels - they work upstream at the NCC transporter. Option D reflects a common misconception; while thiazides become less effective for fluid removal at low GFR, they retain their ability to block NCC transporters and affect electrolyte handling. Remember: thiazide-induced hypokalemia results from enhanced distal potassium secretion due to increased sodium delivery to the collecting duct, regardless of GFR level.

Question 3

A patient with heart failure and renal insufficiency (GFR 35 mL/min) is treated with sacubitril/valsartan. In addition to the hyperkalemic risk from valsartan (an ARB), how does the sacubitril component contribute to this risk?

  1. It inhibits neprilysin, increasing natriuretic peptide levels which suppress aldosterone secretion. (correct answer)
  2. It directly blocks the ROMK channel, preventing potassium secretion.
  3. It induces a state of metabolic acidosis, causing an outward shift of potassium from cells.
  4. It directly inhibits the activity of the Na+/K+-ATPase pump in skeletal muscle and liver.
Explanation: When you encounter questions about combination heart failure medications, focus on how each component's mechanism can create additive effects, especially for electrolyte disturbances. Sacubitril/valsartan combines a neprilysin inhibitor with an ARB. While valsartan blocks angiotensin II receptors (reducing aldosterone and increasing potassium retention), sacubitril adds another layer of hyperkalemic risk through a different pathway. Sacubitril inhibits neprilysin, the enzyme that breaks down natriuretic peptides (BNP, ANP). This leads to elevated natriuretic peptide levels, which have multiple effects including suppression of the renin-angiotensin-aldosterone system. Reduced aldosterone secretion means less potassium excretion in the distal nephron, compounding the hyperkalemic risk from valsartan. This is particularly concerning in patients with renal insufficiency who already have impaired potassium clearance. Option B is incorrect because sacubitril doesn't directly interact with ROMK channels - its effects on potassium handling are mediated through the natriuretic peptide-aldosterone pathway. Option C misrepresents the mechanism; sacubitril doesn't cause metabolic acidosis, and the concern is about renal potassium handling, not cellular shifts. Option D is wrong because sacubitril doesn't inhibit Na⁺/K⁺-ATPase - this would actually cause hyperkalemia through a completely different mechanism unrelated to neprilysin inhibition. Remember: combination medications can create additive risks through different pathways. Always consider how each component's mechanism might compound electrolyte disturbances, especially in patients with compromised renal function.

Question 4

A patient with stable Stage 4 chronic kidney disease (CKD), GFR 20 mL/min, maintains a serum potassium of 5.1 mEq/L on a potassium-restricted diet. Following an episode of acute gastroenteritis with vomiting and diarrhea, their serum potassium acutely rises to 6.3 mEq/L. Which pathophysiologic mechanism best explains this rapid increase in potassium?

  1. Metabolic alkalosis from vomiting, which drives potassium out of the intracellular space.
  2. Reduced distal nephron sodium and water delivery, which impairs flow-dependent potassium secretion. (correct answer)
  3. Increased potassium absorption from the gut due to slowed intestinal transit time.
  4. Acute suppression of aldosterone secretion in response to volume depletion.
Explanation: In advanced CKD, potassium excretion is highly dependent on secretion in the distal nephron, a process that relies on adequate tubular flow and sodium delivery. Gastroenteritis leads to volume depletion, reducing renal perfusion and distal tubular flow. This impairs the ability of the remaining functional nephrons to secrete potassium, causing retention of the daily potassium load and leading to acute hyperkalemia.

Question 5

In the natural history of chronic kidney disease, serum potassium often remains normal until the GFR is profoundly decreased. The eventual development of hyperkalemia in late-stage CKD primarily represents:

  1. a sudden failure of the Na+/K+-ATPase pumps in all body cells.
  2. the saturation of intracellular buffering systems, preventing further potassium uptake.
  3. a fundamental switch from net tubular secretion to net tubular reabsorption of potassium.
  4. the point where the reduced nephron mass can no longer compensate via tubular hypersecretion. (correct answer)
Explanation: The maintenance of potassium balance in early to moderate CKD is a testament to the remarkable adaptive capacity of the kidney, specifically the ability of remaining nephrons to dramatically increase their rate of potassium secretion. Hyperkalemia develops when the disease progresses to a point where the number of functioning nephrons is so critically low that even maximal stimulation and hypersecretion per nephron are insufficient to excrete the daily potassium load. It represents the failure of this compensatory mechanism.

Question 6

In a patient with advanced renal failure, the principal cells of the collecting duct are under maximal stimulation to secrete potassium to maintain homeostasis. Which of the following cellular events is the most critical component of this adaptive response?

  1. Decreased activity of the basolateral Na+/K+-ATPase to conserve cellular ATP.
  2. Enhanced paracellular back-leak of potassium from the lumen into the interstitium.
  3. A significant reduction in the electronegativity of the tubular lumen.
  4. Increased expression and open probability of apical ENaC and ROMK channels. (correct answer)
Explanation: When you encounter questions about renal potassium handling in chronic kidney disease, focus on how the remaining functional nephrons must compensate by dramatically increasing their potassium secretion capacity. In advanced renal failure, the surviving principal cells in the collecting duct face an enormous challenge: they must secrete vastly more potassium per cell to maintain whole-body potassium balance. The most critical adaptation is option D - increased expression and open probability of apical ENaC and ROMK channels. Here's why this works: ENaC (epithelial sodium channels) create the driving force by generating lumen-negative voltage as sodium enters the cell, while ROMK channels provide the pathway for potassium to exit into the urine. Both processes must be dramatically upregulated to achieve maximal secretion. The incorrect options reveal common misconceptions: Option A suggests decreased Na+/K+-ATPase activity, but this pump must actually work harder to maintain the cellular potassium gradient needed for secretion. Option B describes enhanced back-leak, which would be counterproductive - you want to retain secreted potassium in the lumen, not leak it back. Option C proposes reduced electronegativity, but the lumen must become more electronegative (not less) to drive potassium secretion. Remember this key principle: potassium secretion requires three coordinated components - basolateral Na+/K+-ATPase uptake, apical sodium entry (via ENaC) to create driving voltage, and apical potassium exit (via ROMK). In renal failure, all three are upregulated, with the apical channels being the rate-limiting step requiring maximal enhancement.

Question 7

A patient with CKD (GFR 22 mL/min), heart failure, and diabetes is taking lisinopril and spironolactone. They present with a potassium of 6.7 mEq/L. Which of the following factors contributes LEAST to their current state of hyperkalemia?

  1. Reduced filtration of potassium due to the low GFR.
  2. Blockade of the mineralocorticoid receptor by spironolactone.
  3. Reduced aldosterone synthesis due to the effects of lisinopril.
  4. Insulin resistance-mediated impairment of cellular potassium uptake. (correct answer)
Explanation: The patient has three potent reasons for hyperkalemia: 1) severely reduced GFR limiting excretion, 2) lisinopril (an ACE inhibitor) reducing aldosterone production, and 3) spironolactone directly blocking the aldosterone receptor. These three factors profoundly impair renal potassium excretion. While chronic insulin resistance can mildly impair potassium handling, its contribution is far less significant and direct compared to the overwhelming effects of the low GFR and the dual RAAS blockade on renal excretion.

Question 8

A 72-year-old male with CKD (GFR 30 mL/min) is treated with trimethoprim-sulfamethoxazole for a prostate infection. His serum potassium rises from 4.8 to 6.3 mEq/L. The hyperkalemic effect of trimethoprim is mechanistically most similar to that of which of the following medications?

  1. Spironolactone
  2. Lisinopril
  3. Amiloride (correct answer)
  4. Losartan
Explanation: Trimethoprim has a structure similar to the potassium-sparing diuretic amiloride. Like amiloride, trimethoprim directly blocks the epithelial sodium channel (ENaC) on the apical membrane of the principal cells in the collecting duct. This blockade reduces sodium reabsorption, thereby decreasing the lumen-negative potential difference that serves as the driving force for potassium secretion through the ROMK channel. This effect is distinct from spironolactone (aldosterone receptor antagonist) or ACE inhibitors/ARBs like lisinopril/losartan (which reduce aldosterone levels).

Question 9

An elderly patient with CKD Stage 4 (GFR 25 mL/min) begins taking regular high-dose ibuprofen for osteoarthritis. Her serum potassium increases from 5.0 to 6.1 mEq/L. The primary mechanism by which ibuprofen exacerbates hyperkalemia in this setting is:

  1. direct toxic injury to the principal cells of the collecting duct, impairing secretion.
  2. inhibition of renal prostaglandin synthesis, which reduces renin and subsequent aldosterone secretion. (correct answer)
  3. causing a systemic metabolic acidosis that promotes a transcellular shift of potassium.
  4. competitive inhibition of potassium transport at the basolateral membrane of tubular cells.
Explanation: Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen inhibit cyclooxygenase (COX) enzymes, reducing the synthesis of prostaglandins (PGE2 and PGI2). In the kidney, prostaglandins are important for stimulating renin release from the juxtaglomerular apparatus. By inhibiting prostaglandin synthesis, NSAIDs decrease renin secretion, which in turn leads to lower levels of angiotensin II and aldosterone. The resulting hypoaldosteronism impairs distal potassium secretion, a particularly dangerous effect in patients with pre-existing renal insufficiency.

Question 10

Hyperkalemia is often more severe and develops more rapidly in oliguric AKI from rhabdomyolysis than in non-oliguric AKI from aminoglycoside toxicity, even at comparable levels of GFR. What is the most critical reason for this difference?

  1. The combination of impaired renal excretion with a massive, ongoing release of intracellular potassium. (correct answer)
  2. Aminoglycosides selectively spare the potassium-secreting principal cells during tubular injury.
  3. A higher degree of aldosterone resistance induced by myoglobin compared to aminoglycosides.
  4. The preserved distal tubular flow in non-oliguric AKI which allows for some potassium secretion.
Explanation: When you encounter questions comparing different types of AKI and their complications, focus on the underlying mechanisms driving each pathologic process, not just the kidney function itself. Rhabdomyolysis creates a perfect storm for severe hyperkalemia because it combines two devastating factors: kidney injury that impairs potassium excretion AND massive ongoing release of intracellular potassium from damaged muscle cells. Each muscle cell contains about 140 mEq/L of potassium, so widespread muscle breakdown floods the bloodstream with potassium faster than even healthy kidneys could handle. When you add oliguric AKI on top of this cellular potassium dump, hyperkalemia becomes life-threatening rapidly. Choice A correctly identifies this dual mechanism - impaired excretion plus massive cellular release - making it the answer. Choice B is incorrect because aminoglycosides don't selectively spare principal cells; they cause generalized tubular damage, particularly affecting proximal tubules where they concentrate. Choice C misses the mark because aldosterone resistance isn't the primary differentiating factor here. While myoglobin can affect distal nephron function, this doesn't explain the rapid, severe hyperkalemia compared to aminoglycoside toxicity. Choice D actually supports why aminoglycoside toxicity (non-oliguric) would be less severe, but it doesn't address why rhabdomyolysis is worse - it's not just about preserved flow, it's about the massive potassium load. Remember: In pathophysiology questions about AKI complications, always consider both the kidney's ability to handle the problem AND whether there's an increased load being placed on the system.

Question 11

A patient with CKD and hyperkalemia undergoes testing. The transtubular potassium gradient (TTKG) is calculated to be 2.0 (normal with hyperkalemia > 7), while the plasma aldosterone level is markedly elevated. This combination of findings is most consistent with:

  1. excessive dietary potassium intake overwhelming excretory capacity.
  2. hyporeninemic hypoaldosteronism due to diabetic nephropathy.
  3. a state of renal tubular resistance to the action of aldosterone. (correct answer)
  4. surreptitious use of a potassium-sparing diuretic like amiloride.
Explanation: The TTKG is an index of distal potassium secretion. A low TTKG (<5) in the presence of hyperkalemia indicates impaired secretion. The finding of a high plasma aldosterone level shows that the adrenal gland is responding appropriately to the hyperkalemia by producing aldosterone. Therefore, the problem lies not in aldosterone production but in the kidney's response to it. This indicates a state of aldosterone resistance (pseudohypoaldosteronism), where the collecting duct cannot properly secrete potassium despite a strong hormonal signal.

Question 12

A patient with diabetic nephropathy and a GFR of 35 mL/min is started on lisinopril for hypertension. Despite no change in diet or GFR, their serum potassium increases from 4.5 to 5.8 mEq/L over two weeks. This effect is primarily mediated by lisinopril's ability to:

  1. directly block the epithelial sodium channel (ENaC) in the collecting duct, reducing the lumen-negative potential.
  2. inhibit angiotensin II-mediated stimulation of aldosterone synthesis, thereby downregulating potassium secretory channels. (correct answer)
  3. cause a significant transcellular shift of potassium from the intracellular to the extracellular fluid compartment.
  4. acutely reduce renal blood flow and the filtered load of potassium, independent of its effect on GFR.
Explanation: Lisinopril is an ACE inhibitor, which blocks the conversion of angiotensin I to angiotensin II. Angiotensin II is a primary stimulus for aldosterone secretion from the adrenal cortex. By reducing angiotensin II levels, lisinopril decreases aldosterone secretion. Aldosterone is critical for upregulating the activity and expression of ENaC and ROMK channels in the principal cells of the collecting duct, which are responsible for potassium secretion. Reduced aldosterone leads to impaired distal potassium secretion and subsequent hyperkalemia, a risk that is significantly amplified in patients with underlying renal insufficiency.

Question 13

A patient with end-stage renal disease (ESRD) misses a scheduled hemodialysis session and presents with severe hyperkalemia (K+ 6.9 mEq/L) and metabolic acidosis (pH 7.24). What is the direct contribution of the acidemia to the severity of the hyperkalemia?

  1. Inhibition of the basolateral Na+/K+-ATPase pump, preventing potassium from entering cells.
  2. Decreased urinary excretion of potassium due to reduced function of intercalated cells.
  3. Stimulation of H+/K+ exchangers on cell membranes, causing potassium to shift into the extracellular fluid. (correct answer)
  4. Acid-induced cellular lysis, which releases large quantities of intracellular potassium.
Explanation: Metabolic acidosis contributes to hyperkalemia primarily through a transcellular shift. Excess extracellular hydrogen ions (H+) enter cells to be buffered, and in exchange, intracellular potassium (K+) moves into the extracellular fluid to maintain electroneutrality. This exchange is mediated by H+/K+ antiporters on the cell membrane. While acidemia can also inhibit the Na+/K+-ATPase pump, the primary mechanism for the acute shift is the H+/K+ exchange.

Question 14

A 65-year-old male with type 2 diabetes and CKD Stage 3 (GFR 40 mL/min) develops persistent hyperkalemia (K+ 5.9 mEq/L) despite excellent dietary adherence. His labs show a mild, non-anion gap metabolic acidosis. This clinical picture is most suggestive of impaired potassium excretion due to:

  1. overproduction of aldosterone coupled with tubular resistance to its effects.
  2. damage to juxtaglomerular cells leading to impaired renin secretion and hypoaldosteronism. (correct answer)
  3. excessive stimulation of renal H+/K+-ATPase in the setting of chronic insulin resistance.
  4. a primary defect in the function of the ROMK potassium channel in the collecting duct.
Explanation: This patient's presentation is classic for Type 4 renal tubular acidosis (RTA), also known as hyporeninemic hypoaldosteronism. This condition is particularly common in patients with diabetic nephropathy. Damage to the juxtaglomerular apparatus impairs renin secretion, leading to decreased angiotensin II and, consequently, reduced aldosterone production. The relative aldosterone deficiency impairs the distal nephron's ability to secrete both potassium and hydrogen ions, resulting in hyperkalemia and a non-anion gap metabolic acidosis.

Question 15

A patient with diabetic nephropathy and a GFR of 35 mL/min is started on lisinopril for hypertension. Despite no change in diet or GFR, their serum potassium increases from 4.5 to 5.8 mEq/L over two weeks. This effect is primarily mediated by lisinopril's ability to:

  1. directly block the epithelial sodium channel (ENaC) in the collecting duct, reducing the lumen-negative potential.
  2. inhibit angiotensin II-mediated stimulation of aldosterone synthesis, thereby downregulating potassium secretory channels. (correct answer)
  3. cause a significant transcellular shift of potassium from the intracellular to the extracellular fluid compartment.
  4. acutely reduce renal blood flow and the filtered load of potassium, independent of its effect on GFR.
Explanation: Lisinopril is an ACE inhibitor, which blocks the conversion of angiotensin I to angiotensin II. Angiotensin II is a primary stimulus for aldosterone secretion from the adrenal cortex. By reducing angiotensin II levels, lisinopril decreases aldosterone secretion. Aldosterone is critical for upregulating the activity and expression of ENaC and ROMK channels in the principal cells of the collecting duct, which are responsible for potassium secretion. Reduced aldosterone leads to impaired distal potassium secretion and subsequent hyperkalemia, a risk that is significantly amplified in patients with underlying renal insufficiency.

Question 16

In chronic kidney disease (CKD), normokalemia can be maintained until GFR is severely reduced (<15-20 mL/min), whereas in oliguric acute kidney injury (AKI), life-threatening hyperkalemia can develop rapidly. What key adaptive mechanism present in CKD is absent in oliguric AKI?

  1. A significant increase in gastrointestinal potassium excretion via colonic channels.
  2. Enhanced per-nephron potassium secretion in remaining viable nephrons, mediated by aldosterone. (correct answer)
  3. Suppression of renin release from the juxtaglomerular apparatus to limit potassium retention.
  4. Upregulation of proximal tubule potassium reabsorption to conserve filtered bicarbonate.
Explanation: In CKD, as nephron mass is gradually lost, the remaining functional nephrons undergo hypertrophy and increase their individual excretory capacity. This adaptation is largely driven by elevated aldosterone levels and other factors that enhance the activity of secretory channels (e.g., ROMK, BK) in the distal tubule. This allows each nephron to secrete more potassium, compensating for the reduced number of nephrons. In oliguric AKI, the abrupt and widespread loss of tubular function and flow prevents this compensatory hypersecretion from occurring, leading to rapid potassium accumulation.

Question 17

An elderly patient with CKD Stage 4 (GFR 25 mL/min) begins taking regular high-dose ibuprofen for osteoarthritis. Her serum potassium increases from 5.0 to 6.1 mEq/L. The primary mechanism by which ibuprofen exacerbates hyperkalemia in this setting is:

  1. direct toxic injury to the principal cells of the collecting duct, impairing secretion.
  2. inhibition of renal prostaglandin synthesis, which reduces renin and subsequent aldosterone secretion. (correct answer)
  3. causing a systemic metabolic acidosis that promotes a transcellular shift of potassium.
  4. competitive inhibition of potassium transport at the basolateral membrane of tubular cells.
Explanation: Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen inhibit cyclooxygenase (COX) enzymes, reducing the synthesis of prostaglandins (PGE2 and PGI2). In the kidney, prostaglandins are important for stimulating renin release from the juxtaglomerular apparatus. By inhibiting prostaglandin synthesis, NSAIDs decrease renin secretion, which in turn leads to lower levels of angiotensin II and aldosterone. The resulting hypoaldosteronism impairs distal potassium secretion, a particularly dangerous effect in patients with pre-existing renal insufficiency.

Question 18

In a patient with advanced renal failure, the principal cells of the collecting duct are under maximal stimulation to secrete potassium to maintain homeostasis. Which of the following cellular events is the most critical component of this adaptive response?

  1. Decreased activity of the basolateral Na+/K+-ATPase to conserve cellular ATP.
  2. Enhanced paracellular back-leak of potassium from the lumen into the interstitium.
  3. A significant reduction in the electronegativity of the tubular lumen.
  4. Increased expression and open probability of apical ENaC and ROMK channels. (correct answer)
Explanation: When you encounter questions about renal potassium handling in chronic kidney disease, focus on how the remaining functional nephrons must compensate by dramatically increasing their potassium secretion capacity. In advanced renal failure, the surviving principal cells in the collecting duct face an enormous challenge: they must secrete vastly more potassium per cell to maintain whole-body potassium balance. The most critical adaptation is option D - increased expression and open probability of apical ENaC and ROMK channels. Here's why this works: ENaC (epithelial sodium channels) create the driving force by generating lumen-negative voltage as sodium enters the cell, while ROMK channels provide the pathway for potassium to exit into the urine. Both processes must be dramatically upregulated to achieve maximal secretion. The incorrect options reveal common misconceptions: Option A suggests decreased Na+/K+-ATPase activity, but this pump must actually work harder to maintain the cellular potassium gradient needed for secretion. Option B describes enhanced back-leak, which would be counterproductive - you want to retain secreted potassium in the lumen, not leak it back. Option C proposes reduced electronegativity, but the lumen must become more electronegative (not less) to drive potassium secretion. Remember this key principle: potassium secretion requires three coordinated components - basolateral Na+/K+-ATPase uptake, apical sodium entry (via ENaC) to create driving voltage, and apical potassium exit (via ROMK). In renal failure, all three are upregulated, with the apical channels being the rate-limiting step requiring maximal enhancement.

Question 19

In a hypothetical anuric patient with structurally intact cell membranes and hormonal systems, a large intravenous potassium chloride load is administered. In the initial 1-2 hours, the primary physiological defense mechanism against life-threatening hyperkalemia would be:

  1. stimulation of insulin and catecholamines, promoting intracellular uptake via Na+/K+-ATPase. (correct answer)
  2. secretion of potassium into the gastrointestinal tract mediated by aldosterone.
  3. binding of excess potassium to plasma proteins such as albumin.
  4. a rapid increase in the glomerular filtration rate to excrete the potassium load.
Explanation: When you encounter questions about acute hyperkalemia management, focus on the timeline and available compensatory mechanisms. The body has multiple defenses against dangerous potassium elevation, but they operate on different timescales. In acute hyperkalemia, the most rapid defense is shifting potassium from extracellular to intracellular compartments. Answer A correctly identifies this mechanism: insulin and catecholamines (epinephrine, norepinephrine) are released within minutes and directly stimulate the Na⁺/K⁺-ATPase pump. This pump actively transports potassium into cells, rapidly lowering serum levels before cardiac arrhythmias develop. The hormonal response is immediate and doesn't require functioning kidneys. Answer B describes aldosterone-mediated gastrointestinal potassium secretion, which does occur but takes hours to days to become significant. While the colon can increase potassium secretion, this mechanism is too slow for acute management within 1-2 hours. Answer C is incorrect because potassium doesn't bind significantly to plasma proteins like albumin. Potassium exists primarily as free ions in solution, which is why changes in serum levels directly affect membrane potentials. Answer D fails because the patient is anuric (producing no urine), indicating severe renal dysfunction. Even if glomerular filtration could increase, it wouldn't help someone who cannot produce urine. Remember this pattern: acute hyperkalemia management follows a three-step timeline: immediate cellular shifts (insulin/catecholamines), intermediate membrane stabilization (calcium), and delayed elimination (dialysis when kidneys fail). Always consider what mechanisms can work fastest when organs are compromised.

Question 20

A 72-year-old male with CKD (GFR 30 mL/min) is treated with trimethoprim-sulfamethoxazole for a prostate infection. His serum potassium rises from 4.8 to 6.3 mEq/L. The hyperkalemic effect of trimethoprim is mechanistically most similar to that of which of the following medications?

  1. Spironolactone
  2. Lisinopril
  3. Amiloride (correct answer)
  4. Losartan
Explanation: Trimethoprim has a structure similar to the potassium-sparing diuretic amiloride. Like amiloride, trimethoprim directly blocks the epithelial sodium channel (ENaC) on the apical membrane of the principal cells in the collecting duct. This blockade reduces sodium reabsorption, thereby decreasing the lumen-negative potential difference that serves as the driving force for potassium secretion through the ROMK channel. This effect is distinct from spironolactone (aldosterone receptor antagonist) or ACE inhibitors/ARBs like lisinopril/losartan (which reduce aldosterone levels).